Advanced glycation end products and advanced oxidation protein products in hemodialyzed patients

Blood Purification

Volumn 20, Issue 6, 2002, Pages 531-536

  Kalousová, Marta ^a   Zima, T ^a   Tesar V ^a   Lachmanova J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Advanced glycation end products; Advanced oxidation protein products; Carbonyl stress; Hemodialysis; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED OXIDATION PROTEIN PRODUCT; BIOLOGICAL MARKER; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEMODIALYSIS; HUMAN; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; SPECTROFLUOROMETRY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHLORAMINES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OXIDATIVE STRESS; RENAL DIALYSIS; SPECTROMETRY, FLUORESCENCE; TIME FACTORS;

EID: 0036948304     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066956     Document Type: Article

References (40)

1. Miyata T, Maeda K, Kurokawa K, van Ypersele de Strihou C: Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol Dial Transplant 1997;12:255-258.
2. Halliwell B: Drug antioxidants effects: A basis for drug selection? Drugs 1991;42:569-605.
3. Miyata T, van Ypersele de Strihou, Kurokawa K, Baynes JW: Alterations in nonenzymatic biochemistry in uremia: Origin and significance of 'carbonyl stress' in long-term uremic complications. Kidney Int 1999;55:389-399.
4. Witko Sarsat V, Friedlander M, Capeillere-Blandin Ch, Nguyen-Khoa Thao, Nguyen AT, Zingraff J, Jungers P, Deschmps-Latscha B: Advanced oxidation protein products as a novel marker of oxidative stress in ureamia. Kidney Int 1996;49:1304-1313.
5. Zima T, Štípek S, Crkovská J, Němecěk K, Pláteník J, Bártová V, Tesař V: Antioxidant enzymes - superoxide dismutase and glutathione peroxidase in haemodialysis patients. Blood Purif 1996;14:257-261.
6. Loughrey CM, Young IS, Lightbody JH, McMaster D, McNamee PT, Trimble ER: Oxidative stress in haemodialysis. Q J Med 1994;87:679-683.
7. Nguyen-Khoa T, Massy ZA, De Bandt JP, Kebede M, Salama L, Lambrey G, Witko-Sarsat V, Drueke TB, Lacour B, Thevenin M: Oxidative stress and haemodialysis: Role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 2001;16:335-340.
8. Miyata T, Fu MX, Kurokawa K, van Ypersele de Strihou Ch, Thorpe S, Baynes JW: Auto-oxidation products of both carbohydrates and lipids are increased in uremic plasma: Is there oxidative stress in uremia? Kidney Int 1998;54:1290-1295.
9. Miayta T, Kurokawa K, van Ypersele de Strihou C: Relevance of oxidative stress to long-term uremic complications. Kidney Int 2000;58:S120-S125.
10. Vlassara H: Recent progress in advanced glycation end products and diabetic complications. Diabetes 1997;46:S19-S25.
11. Munch G, Gerlach M, Sian J, Wong A, Riederer P: Advanced glycation end products in neurodegeneration: More than early markers of oxidative stress? Ann Neurol 1998;44:S85-S88.
12. Korbet SM, Makita Z, Firanek C A, Vlassara H: Advanced glycosylation end products in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1993;22:588-591.
13. Henle T, Deppisch R, Beck W, Hergesell O, Hansch G, Ritz E: Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogenity of AGE compounds. Nephrol Dial Transplant 1999;14:1968-1975.
14. Gerdermann A, Solf O, Heidland A, Vienken J, Bahner U, Schinzel R: Comparison of the removal of advanced glycation end products (AGEs) in hemodialysis, hemofiltration and hemodiafiltration. Abstracts. Symposium Advanced glycation end products (AGEs), Jena, 2000.
15. Tessitore N, Lapolla A, Arico CN, Gammaro L, Bernich P, Fedel D: Hemodialysis techniques and advanced glycation end products; in D'Angelo A, Favaro S, Gambaro G (eds): Advanced Glycation End Products in Nephrology. Contrib Nephrol. Basel, Karger, 2001, vol 131, pp 33-39.
16. Krieter DH, Lemke HD, Gerdermann A, Schinzel R, Heidland A, Baumeister U: Effect of LDL apheresis on the removal of advanced glycation end products (AGE). Abstracts. 37th ERA-EDTA Congress, Nice, 2000.
17. Lee WK, Akyol M, Shaw S, Dominiczak MH, Briggs JD: Kidney transplantation decreases the tissue level of advanced glycosylation end-products. Nephrol Dial Transplant 1995;10:103-107.
18. Wieslander A, Linden T, Musí B, Jarkelid L, Speidel R, Beck W, Henle T, Deppisch R: Exogenous uptake of carbonyl stress compounds promoting AGE formation from peritoneal dialysis fluids; in D'Angelo A, Favaro S, Gambaro G (eds): Advanced Glycation End Products in Nephrology. Contrib Nephrol. Basel, Karger, 2001, vol 131, pp 82-89.
19. Zeier M, Deppisch R, Haug U, Schwenger V, Henle T, Bahner U, Wanner C, Schneider H, Ritz E: Resorption of AGE-promoting glucose degradation products (GDP) from peritoneal dialysis (PD) fluids leads to increased levels of AGE in plasma. J Am Soc Nephrol 2000;11:223A.
20. Witko-Sarsat V, Friedlander M, Nguyen-Khoa T, Capeillere-Blamdin Ch, Nguyen AH, Canteloup S, Drayer JM, Jungers P, Drueke T, Deschamps-Latscha B: Advanced oxidation protein products as novel mediator of inflammation and monocyte activation in chronic renal failure. J Immunol 1998;161:2524-2532.
21. Buonocore G, Perrone S, Longini M, Terzuoli L, Bracci R: Total hydroperoxide and advanced oxidation protein products in preterm hypoxic babies. Pediatr Res 2000;47:221-224.
22. Munch G, Kies R, Wessel A, Riederer P, Bahner U, Heidland A, Niwa T, Lemke HD, Schinzel R: Determination of advanced glycation and products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 1997;35:669-677.
23. Kalousová M, Zima T, Tesař V, Škrha J, Štípek S: Determination of advanced glycation end products and advanced oxidation protein products. Klin Bioch Metab 2002;10:11-16.
24. Doumas BT, Bayse DD, Carter RJ, Peters T Jr, Schaffer R: A candidate reference method for determination of total protein in serum. I. Development and validation. Clin Chem 1981;27:1642-1650.
25. Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, Korbet SM, Barth RH, Winston JA, Fuh H, Manogue KR, Cerami A, Vlassara H: Reactive glycosylation end-products in diabetic uremia and treatment of renal failure. Lancet 1994;343:1519-1522.
26. Stein G, Krankle S, Mahiout A, Schneider S, Sperschneider H, Borst S, Vienken J: Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients. Nephrol Dial Transplant 2001;16:999-1008.
27. Miyata T, Ueda Y, Yoshida A, Sugiyama S, Iida Y, Jadoul M, Maeda K, Kurokawa K, van Ypersele de Strihou C: Clearance of pentosidine, an advanced glycation end products, by different modalities of renal replacement therapy. Kidney Int 1997;51:880-887.
28. Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oreopoulos D, Diamandis EP: Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 1994;46:216-222.
29. Dolhofer-Bliesener R, Lechner B, Deppisch R, Ritz E, Gerbitz KD: Immunological determination of advanced glycosylation end-products in human blood and urine. Nephrol Dial Transplant 1995;10:657-664.
30. Vlassara H: Serum advanced glycosylation end products: A new class of uremic toxins? Blood Purif 1994;12:54-59.
31. Himmelfarb J, McMenamin ME, Loseto G, Heinecke JW: Meyloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patients. Free Radic Biol Med 2001;31:1163-1169.
32. Kormoczi GF, Rosenkranz AR, Zlabinger GJ: Polymorphonyclear granulocyte stimulation by cellulose-based hemodialysis membranes. Clin Chem Lab Med 1999;37:351-355.
33. Rousseau Y, Carreno MP, Poignet JL, Kazatchkine MD, Haeffner-Cavaillon: Dissociation between complement activation, integrin expression and neutropenia during hemodialysis. Biomaterials 1999;20:1959-1567.
34. Castaldello K, Husson C, Wens R, Jean-Louis Vanherweghem Tielemans C: Role of complement and platelet-activation factor in the stimulation of phagocytosis and reactive oxygen species products during haemodialysis. Nephrol Dial Transplant 2000;15:1638-1646.
35. Zima T, Haragsim L, Stipek S, Bartova V, Nemecek K: Lipid peroxidation on dialysis membrane. Biochem Mol Biol Int 1993;29:531-537.
36. Descamps-Latscha B, Witko-Sarsat V: Importance of oxidatively modified proteins in chronic renal failure. Kidney Int 2001;59:S108-S113.
37. Schwedler S, Schinzel R, Vaith P, Wanner C: Inflammation and advanced glycation end products in uremia: Simple coexistence, potential or casual relationship? Kidney Int 2001;59:S32-S36.
38. Menzel E J, Sobal G, Staudinger A: The role of oxidative stress in the long-term glycation of LDL. Biofactors 1997;6:111-124.
39. Acosta J, Hettinga J, Fluckiger R, Krumrei N, Goldfine A, Angarita L, Halperin J: Molecular basis for a link between complement and the vascular complications of diabetes. PNAS 2000;97:5450-5455.
40. Deppisch RM, Beck W, Goehl H, Ritz E: Complement components as uremic toxins and their potential role as mediators of microinflammation. Kidney Int 2001;59:S271-S277.